ABAC Therapeutics
http://www.abactherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ABAC Therapeutics
REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry
As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.
Venture Funding Deals: Celularity Launches With $250m; Generation Bio Grabs $100m Series B
Celularity launched with $250m to develop cell therapies with technology licensed from Celgene and others, while mRNA specialist Moderna brought in another $500m mega round and Generation Bio closed a $100m Series B to fund ongoing gene therapy programs.
Novo $165m Superbug Fund is Fillip For Antibiotic Start-Ups
REPAIR will invest $20–40m per year over three–five years in 20 projects to combat antimicrobial resistance, with the hope that at least one of them will get to market.
ABAC Chief Calls For Better Antibiotic R&D Incentives In Europe
Fresh from raising €16m in a Series A round, Albert Palomer, CEO of Spain's ABAC Therapeutics, has outlined to Scrip the company's pathogen-specific approach to antibiotic research and his fears that biotechs in Europe are being held back by flaws in the continent's 'push' incentives schemes.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice